HRP20170745T1 - Kristalni oblik natrijeve soli 4-tert-butil-n-[4-kloro-2-(1-oksipiridin-4-karbonil)-fenil]-benzensulfonamida - Google Patents
Kristalni oblik natrijeve soli 4-tert-butil-n-[4-kloro-2-(1-oksipiridin-4-karbonil)-fenil]-benzensulfonamida Download PDFInfo
- Publication number
- HRP20170745T1 HRP20170745T1 HRP20170745TT HRP20170745T HRP20170745T1 HR P20170745 T1 HRP20170745 T1 HR P20170745T1 HR P20170745T T HRP20170745T T HR P20170745TT HR P20170745 T HRP20170745 T HR P20170745T HR P20170745 T1 HRP20170745 T1 HR P20170745T1
- Authority
- HR
- Croatia
- Prior art keywords
- crystalline form
- degrees
- group
- disease
- peaks
- Prior art date
Links
- 159000000000 sodium salts Chemical class 0.000 title claims 2
- 238000001237 Raman spectrum Methods 0.000 claims 4
- 238000002441 X-ray diffraction Methods 0.000 claims 4
- 239000000843 powder Substances 0.000 claims 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 2
- 206010058284 Allergy to arthropod sting Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010013700 Drug hypersensitivity Diseases 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 208000005141 Otitis Diseases 0.000 claims 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046914 Vaginal infection Diseases 0.000 claims 1
- 201000008100 Vaginitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 108010089833 chemokine receptor D6 Proteins 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000019258 ear infection Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000009326 ileitis Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000030428 polyarticular arthritis Diseases 0.000 claims 1
- 208000012102 polyarticular juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (12)
1. Kristalni oblik bezvodne natrijeve soli 4-tert-butil-N-[4-kloro-2-(1-oksipiridin-4-karbonil)-fenil]-benzensulfonamida pri čemu je kristalni oblik naznačen time da rendgenska difrakcijska slika praha sadrži najmanje tri difrakcijska kuta, kada se mjeri pomoću Cu K, zračenja, koji su odabrani iz skupine koja se sastoji od: 4,7, 9,1, 12,0, 14,2, 17,7, 18,1, 19,2, 19,8, 20,1, 21,3, 22,5, 24,3, 27,0, 27,2, 27,7, 28,6, 28,8, 29,0, 30,1, 31,6, 33,5, 33,6 i 37,6 stupnjeva 2θ ±0,2 stupnja 2θ.
2. Kristalni oblik iz zahtjeva 1., pri čemu je kristalni oblik naznačen time da rendgenska difrakcijska slika praha sadrži najmanje tri difrakcijska kuta odabrana iz skupine koja se sastoji od: 4,7, 9,1, 12,0, 14,2, 18,1, 19,2, 19,8, 20,1, 21,3, 22,5, 24,3, 27,2, 28,8 i 37,6 stupnjeva 2θ ±0,2 stupnja 2θ.
3. Kristalni oblik iz zahtjeva 1., pri čemu je kristalni oblik naznačen time da rendgenska difrakcijska slika praha sadrži najmanje tri difrakcijska kuta odabrana iz skupine koja se sastoji od: 4,7, 12,0, 14,2, 18,1, 19,2 i 24,3 stupnja 2θ ±0,2 stupnja 2θ.
4. Kristalni oblik iz zahtjeva 1., pri čemu je kristalni oblik naznačen time da rendgenska difrakcijska slika praha sadrži difrakcijske kutove odabrane iz skupine koja se sastoji od: 4,7, 12,0, 14,2, 18,1, 19,2 i 24,3 stupnja 2θ ±0,2 stupnja 2θ.
5. Kristalni oblik iz bilo kojeg od zahtjeva 1. – 4., pri čemu je kristalni oblik naznačen time da Ramanov spektar sadrži najmanje tri vrha u položajima odabranim iz skupine koja se sastoji od: 601, 632, 651, 664, 726, 740, 803, 853, 931, 1080, 1123, 1138, 1162, 1318, 1395, 1458, 1526, 1595, 1614 i 1647 cm-1 ±4 cm-1.
6. Kristalni oblik iz bilo kojeg od zahtjeva 1. – 5., pri čemu je kristalni oblik naznačen time da Ramanov spektar sadrži najmanje tri vrha u položajima odabranim iz skupine koja se sastoji od: 664, 740, 803, 853, 1080, 1123, 1162, 1318, 1458, 1526, 1595, 1614 i 1647 cm-1 ±4 cm-1.
7. Kristalni oblik iz bilo kojeg od zahtjeva 1. – 5., pri čemu je kristalni oblik naznačen time da Ramanov spektar sadrži najmanje tri vrha u položajima odabranim iz skupine koja se sastoji od: 664, 1162, 1458, 1614 i 1647 cm-1 ±4 cm-1.
8. Kristalni oblik iz bilo kojeg od zahtjeva 1. – 5., pri čemu je kristalni oblik naznačen time da Ramanov spektar sadrži vrhove u položajima odabranim iz skupine koja se sastoji od: 664, 740, 803, 853, 1080, 1123, 1162, 1318, 1458, 1526, 1595, 1614 i 1647 cm-1 ±4 cm-1.
9. Farmaceutski sastav koji sadrži kristalni oblik prema bilo kojem od zahtjeva 1. – 8. i farmaceutski prihvatljiv nositelj.
10. Kristalni oblik prema bilo kojem od zahtjeva 1. – 8. ili sastav iz zahtjeva 9. za primjenu u liječenju upalne bolesti crijeva.
11. Kristalni oblik za primjenu ili sastav za primjenu prema zahtjevu 10., pri čemu upalna bolest crijeva znači Crohnova bolest ili ulcerozni kolitis.
12. Kristalni oblik prema bilo kojem od zahtjeva 1. – 8. ili sastav iz zahtjeva 9. za primjenu u liječenju nekog od sljedećih poremećaja kojima posreduje kemokinski receptor CCR9: generalizirana anafilaksija, odgovori preosjetljivosti, alergije na lijekove, alergije na ubode insekata, alergije na hranu, Crohnova bolest, ulcerozni kolitis, ileitis i enteritis, vaginitis, psorijaza, dermatitis, ekcem, atopički dermatitis, alergijski kontaktni dermatitis, urtikarija, pruritus, vaskulitis, spondiloartropatije, sklerodermija, astma, fibromialgija, sklerodermija, ankilozirajući spondilitis, juvenilni reumatoidni artritis, Stillova bolest, poliartikularni juvenilni reumatoidni artritis, oligoartikularni juvenilni reumatoidni artritis, reumatska polimialgija, reumatoidni artritis, psorijatični artritis, osteoartritis, poliartikularni artritis, multipla skleroza, sistemni lupus eritematodes, dijabetes tipa I, dijabetes tipa II, glomerulonefritis, odbacivanje transplantata, akutna i kronična ateroskleroza koja je posljedica reakcije transplantata prema domaćinu, miozitis, Alzheimerova bolest, encefalitis, meningitis, hepatitis, nefritis, sepsa, sarkoidoza, alergijski konjuktivitis, otitis, kronična opstruktivna bolest pluća, sinusitis, Behçetov sindrom, giht, plućna fibroza i sindrom iritabilnog crijeva.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161510832P | 2011-07-22 | 2011-07-22 | |
| EP12741219.5A EP2748146B1 (en) | 2011-07-22 | 2012-07-20 | A crystalline form of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide |
| PCT/US2012/047559 WO2013016174A1 (en) | 2011-07-22 | 2012-07-20 | A crystalline form of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170745T1 true HRP20170745T1 (hr) | 2017-08-11 |
Family
ID=46599010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170745TT HRP20170745T1 (hr) | 2011-07-22 | 2017-05-18 | Kristalni oblik natrijeve soli 4-tert-butil-n-[4-kloro-2-(1-oksipiridin-4-karbonil)-fenil]-benzensulfonamida |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9133124B2 (hr) |
| EP (1) | EP2748146B1 (hr) |
| JP (1) | JP6122003B2 (hr) |
| CN (1) | CN103842343B (hr) |
| AU (1) | AU2012287160B2 (hr) |
| BR (1) | BR112014001299B1 (hr) |
| CA (1) | CA2841967C (hr) |
| DK (1) | DK2748146T3 (hr) |
| ES (1) | ES2625286T3 (hr) |
| HR (1) | HRP20170745T1 (hr) |
| HU (1) | HUE032747T2 (hr) |
| IL (1) | IL230468B (hr) |
| MX (1) | MX350269B (hr) |
| PL (1) | PL2748146T3 (hr) |
| PT (1) | PT2748146T (hr) |
| RS (1) | RS56023B1 (hr) |
| RU (1) | RU2607515C2 (hr) |
| SI (1) | SI2748146T1 (hr) |
| WO (1) | WO2013016174A1 (hr) |
| ZA (1) | ZA201400474B (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2842894A1 (en) * | 2011-07-22 | 2013-01-31 | Chemocentryx, Inc. | Polymorphic forms of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide |
| RU2607191C2 (ru) * | 2011-07-22 | 2017-01-10 | Хемоцентрикс, Инк. | Полиморфные формы натриевой соли 4-трет-бутил-n-[4-хлор-2-(1-окси-пиридин-4-карбонил)-фенил]-бензолсульфонамида |
| EP3141235A1 (en) * | 2012-12-06 | 2017-03-15 | IP Gesellschaft für Management mbH | N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorobenzylthio)pyrimidin-4-yl)-3-methylazetidine-l -sulfonamide |
| US9822057B2 (en) | 2013-03-14 | 2017-11-21 | United Therapeutics Corporation | Solid forms of treprostinil |
| JP6954834B2 (ja) | 2014-10-06 | 2021-10-27 | ケモセントリックス，インコーポレイティド | ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法 |
| US10792360B1 (en) | 2019-11-21 | 2020-10-06 | Chemocentryx, Inc. | Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies |
| TW202203916A (zh) | 2020-03-31 | 2022-02-01 | 美商卡默森屈有限公司 | 使用ｃｃｒ９抑制劑及抗ｉｌ—２３阻斷抗體治療發炎性腸道疾病的組成物及方法 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4826689A (en) | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
| FR2634376B1 (fr) | 1988-07-21 | 1992-04-17 | Farmalyoc | Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation |
| IT1227626B (it) | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
| IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| ATE150297T1 (de) | 1992-06-10 | 1997-04-15 | Nanosystems Llc | Oberflaechenmodifizierte nsaid nanopartikeln |
| AU660852B2 (en) | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
| US5298262A (en) | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
| US5346702A (en) | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
| US5302401A (en) | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
| US5340564A (en) | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
| US5336507A (en) | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
| US5429824A (en) | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
| US5352459A (en) | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
| US5587143A (en) | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5585108A (en) | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
| US5560932A (en) | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
| US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
| US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
| US5569448A (en) | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5560931A (en) | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5571536A (en) | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5503723A (en) | 1995-02-08 | 1996-04-02 | Eastman Kodak Company | Isolation of ultra small particles |
| US5518738A (en) | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
| US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5622938A (en) | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
| US5591456A (en) | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
| US5573783A (en) | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
| US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| US5718919A (en) | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
| US5565188A (en) | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
| US5747001A (en) | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
| WO1998035666A1 (en) | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
| MXPA04011465A (es) * | 2002-05-24 | 2005-02-14 | Millennium Pharm Inc | Inhibidores de ccr9 y metodos de uso de los mismos. |
| DK1562940T3 (da) * | 2002-11-18 | 2007-10-01 | Chemocentryx Inc | Arylsulfonamider |
| US20050250820A1 (en) * | 2004-03-08 | 2005-11-10 | Amgen Inc. | Therapeutic modulation of PPARgamma activity |
| CA2566387A1 (en) * | 2004-05-12 | 2005-12-01 | Chemocentryx, Inc. | Aryl sulfonamides as chemokine receptor ccr9 antagonists |
| ATE498615T1 (de) * | 2006-07-14 | 2011-03-15 | Chemocentryx Inc | Triazolylphenylbenzensulfonamide |
| US20100234364A1 (en) * | 2006-07-14 | 2010-09-16 | Arindrajit Basak | Ccr2 inhibitors and methods of use thereof |
| US8519135B2 (en) * | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
| RU2607191C2 (ru) * | 2011-07-22 | 2017-01-10 | Хемоцентрикс, Инк. | Полиморфные формы натриевой соли 4-трет-бутил-n-[4-хлор-2-(1-окси-пиридин-4-карбонил)-фенил]-бензолсульфонамида |
| CA2842894A1 (en) * | 2011-07-22 | 2013-01-31 | Chemocentryx, Inc. | Polymorphic forms of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide |
-
2012
- 2012-07-20 JP JP2014522898A patent/JP6122003B2/ja active Active
- 2012-07-20 MX MX2014000660A patent/MX350269B/es active IP Right Grant
- 2012-07-20 RU RU2014104993A patent/RU2607515C2/ru active
- 2012-07-20 SI SI201230957T patent/SI2748146T1/sl unknown
- 2012-07-20 DK DK12741219.5T patent/DK2748146T3/en active
- 2012-07-20 HU HUE12741219A patent/HUE032747T2/en unknown
- 2012-07-20 AU AU2012287160A patent/AU2012287160B2/en active Active
- 2012-07-20 BR BR112014001299-7A patent/BR112014001299B1/pt active IP Right Grant
- 2012-07-20 ES ES12741219.5T patent/ES2625286T3/es active Active
- 2012-07-20 PL PL12741219T patent/PL2748146T3/pl unknown
- 2012-07-20 EP EP12741219.5A patent/EP2748146B1/en active Active
- 2012-07-20 PT PT127412195T patent/PT2748146T/pt unknown
- 2012-07-20 WO PCT/US2012/047559 patent/WO2013016174A1/en active Application Filing
- 2012-07-20 US US13/554,169 patent/US9133124B2/en active Active
- 2012-07-20 RS RS20170505A patent/RS56023B1/sr unknown
- 2012-07-20 CA CA2841967A patent/CA2841967C/en active Active
- 2012-07-20 CN CN201280036358.9A patent/CN103842343B/zh active Active
-
2014
- 2014-01-15 IL IL230468A patent/IL230468B/en active IP Right Grant
- 2014-01-21 ZA ZA2014/00474A patent/ZA201400474B/en unknown
-
2017
- 2017-05-18 HR HRP20170745TT patent/HRP20170745T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20130059893A1 (en) | 2013-03-07 |
| IL230468B (en) | 2018-05-31 |
| DK2748146T3 (en) | 2017-05-22 |
| AU2012287160A1 (en) | 2014-02-06 |
| AU2012287160B2 (en) | 2017-02-02 |
| EP2748146A1 (en) | 2014-07-02 |
| HUE032747T2 (en) | 2017-10-30 |
| CA2841967C (en) | 2020-06-16 |
| MX2014000660A (es) | 2014-07-09 |
| CN103842343B (zh) | 2016-08-31 |
| BR112014001299B1 (pt) | 2022-08-16 |
| PL2748146T3 (pl) | 2017-09-29 |
| ES2625286T3 (es) | 2017-07-19 |
| MX350269B (es) | 2017-08-31 |
| RS56023B1 (sr) | 2017-09-29 |
| CA2841967A1 (en) | 2013-01-31 |
| US9133124B2 (en) | 2015-09-15 |
| ZA201400474B (en) | 2015-03-25 |
| SI2748146T1 (sl) | 2017-10-30 |
| WO2013016174A1 (en) | 2013-01-31 |
| JP6122003B2 (ja) | 2017-04-26 |
| JP2014524931A (ja) | 2014-09-25 |
| RU2014104993A (ru) | 2015-11-20 |
| PT2748146T (pt) | 2017-05-29 |
| IL230468A0 (en) | 2014-03-31 |
| CN103842343A (zh) | 2014-06-04 |
| RU2607515C2 (ru) | 2017-01-10 |
| BR112014001299A2 (pt) | 2017-01-10 |
| EP2748146B1 (en) | 2017-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170745T1 (hr) | Kristalni oblik natrijeve soli 4-tert-butil-n-[4-kloro-2-(1-oksipiridin-4-karbonil)-fenil]-benzensulfonamida | |
| HRP20200775T1 (hr) | Novi derivati amino-pirimidina | |
| RU2016110852A (ru) | Ингибиторы irak и их применения | |
| CY1112805T1 (el) | Παραγωγα πυραζολο (3,4-b) πυριδινης ως αναστολεις της φωσφοδιεστερασης | |
| HRP20210036T1 (hr) | Soli inhibitora pi3k i postupci za njihovo dobivanje | |
| HRP20140609T1 (hr) | Äśvrsti oblici koji sadrže (+)-2-[1-(3-etoksi-4-metoksifenil)-2-metilsulfoniletil]-4-acetilaminoizoindolin-1,3-dion, njegovi pripravci i njihova upotreba | |
| WO2015140051A8 (en) | Heteroaryl syk inhibitors | |
| DK2170769T3 (da) | Krystalliseret faststof IZM-2 og fremgangsmåde til fremstilling deraf | |
| SI2956452T1 (en) | Heterocyclic amides as kinase inhibitors | |
| HRP20210455T1 (hr) | Anti-orai1 antitijelo | |
| Baumer et al. | Glass transition by gelation in a phase separating binary alloy | |
| CL2017000773A1 (es) | Proceso para la producción de granulados de sulfato de potasio y el granulado de sulfato de potasio obtenido a partir del mismo, así como también su uso. | |
| RU2016123088A (ru) | Физически модифицированный крахмал саго | |
| WO2009115874A3 (en) | Novel heterocyclic compounds, pharmaceutical compositions containing them and processes for their preparation | |
| CN103524406A (zh) | 一种2,3-二氟-5-氯吡啶的纯化方法 | |
| EA201590248A1 (ru) | Связующее на основе доменного шлака | |
| Alamdari et al. | Synthesis and thermal characterization of mono and dicationic imidazolium pyridinium based ionic liquids | |
| Gao et al. | Solubility of AlCl3· 6H2O in the Fe (II)+ Mg+ Ca+ K+ Cl+ H2O system and its salting-out crystallization with FeCl2 | |
| JP2018537499A5 (hr) | ||
| RU2018122953A (ru) | Новые производные диаминопиридина | |
| Zhang et al. | Kinetics of glass transition of Ce65Al20Co15 metallic glass | |
| El-Naggar et al. | Synthesis and equilibrium studies of titanium vanadate and its use in the removal of some hazardous elements | |
| Murayama et al. | Synthesis of Layered Double Hydroxide from Steelmaking Slag and its Evaluation | |
| Kabir et al. | AC electrical conductivity and dielectric properties of doping induced molecular ferroelectric diisopropylammonium bromide | |
| Pérez Colodrero et al. | PXRD and PDF analysis of multifunctional lanthanide nitrilotris-methylphosphonate-based proton conductors |